DaVita Inc. (NYSE:DVA) Stock Has Average Price Target of $233.43 According to Analysts

DaVita Inc. (NYSE:DVA) has earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $233.43.

Several equities analysts have recently weighed in on DVA shares. Barclays raised their price target on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. Oppenheimer set a $220.00 target price on shares of DaVita in a report on Friday, August 7th. UBS Group raised their price target on shares of DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Finally, Raymond James Financial set a $220.00 price target on DaVita in a research note on Friday, August 7th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Berkshire Hathaway Inc purchased a new stake in DaVita during the 2nd quarter valued at $6,425,269,000. BlackRock Inc. bought a new stake in shares of DaVita in the second quarter worth $547,520,000. Dimensional Fund Advisors LP increased its position in DaVita by 5.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company’s stock valued at $176,037,000 after acquiring an additional 56,336 shares during the last quarter. Bank of America Corp DE bought a new position in DaVita in the second quarter valued at about $145,057,000. Finally, Arrowstreet Capital Limited Partnership boosted its position in DaVita by 114.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock worth $135,196,000 after purchasing an additional 636,191 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

Shares of DVA opened at $174.71 on Friday. The firm’s 50-day simple moving average is $195.40 and its two-hundred day simple moving average is $187.74. DaVita has a fifty-two week low of $101.00 and a fifty-two week high of $247.49. The stock has a market cap of $11.15 billion, a PE ratio of 14.30, a price-to-earnings-growth ratio of 0.48 and a beta of 0.83.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, topping the consensus estimate of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. During the same quarter in the prior year, the business posted $2.95 EPS. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts predict that DaVita will post 14.57 EPS for the current year.

About DaVita

DaVita Inc (NYSE: DVA) is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.

DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.